USPTO serial 90454887
BELLA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SALES, HEATHER ALISON
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BELLA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kimberly S. Grimsley
Kimberly S. Grimsley OLIVER & GRIMSLEY, LLC1 OLYMPIC PLACESUITE 900TOWSON, MD 21204Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | COVID-19 rapid tests comprising reagents and assays for withdrawing and testing respiratory droplets for clinical, medical laboratory, research, and scientific purposes and also including parts and fittings thereof | ACTIVE | — |
| 005 | Diagnostic kits comprised of medical diagnostic assays for use in disease detection, screening, treating and monitoring, namely, monitoring COVID-19 and other infectious diseases; Respiratory rapid tests, namely, medical diagnostic assays for use in performing respiratory rapid tests related to COVID-19 and other infectious diseases; Medical diagnostic kits comprised of reagents and assays for use in disease detection, screening, treating and monitoring, including, monitoring COVID-19 and other infectious diseases and also including swabs, including nasal and throat swabs, and medical sample tubes; COVID-19 rapid tests comprising medical diagnostic reagents and assays for withdrawing and testing respiratory droplets and also including parts and fittings thereof | ACTIVE | — |
| 009 | Downloadable computer application software for mobile phones, namely, software for covid-19 and other infectious disease identification; Downloadable computer application software for computers, namely, software for covid-19 and other infectious disease identification; Downloadable mobile applications for health screenings relating to COVID-19 and other infectious disease; Downloadable mobile applications for tracking and reporting health conditions and symptoms; Medical, clinical, and scientific laboratory research instruments for identifying and testing pathogens and biomarkers in respiratory droplets related to COVID-19 and other infectious diseases; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for clinical and medical laboratory research, and scientific purposes, namely, for COVID-19 and other infectious diseases | ACTIVE | — |
| 010 | Medical instruments, namely, biosensors for detecting Covid-19 and other infectious diseases in a patient; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for medical diagnostic purposes, namely, for COVID-19 and other infectious diseases | ACTIVE | — |
| 042 | Providing temporary use of online non-downloadable software for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; Scientific apparatus and instruments, namely, COVID-19 rapid tests for withdrawing and testing respiratory droplets for clinical, medical, research, and scientific purposes and parts and fittings thereof; Material testing apparatus and instruments, for identifying and testing pathogens and biomarkers in respiratory droplets for clinical, medical, research, and scientific purposes related to COVID-19 and other infectious diseases; Apparatus for transmission of communication; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for clinical, medical, research, and scientific purposes, namely, for COVID-19 and other infectious diseases; Providing temporary use of online non-downloadable software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Providing temporary use of web-based software applications for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Software as a service (SAAS) services featuring software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Electronic storage of information concerning persons infected with contagious disease for the purpose slowing or stopping the spread of the disease under the guidance of state and local public health departments, and information concerning physical sites visited by persons infected with contagious disease for the purpose slowing or stopping the spread of the disease under the guidance of state and local public health departments | ACTIVE | — |
| 044 | Healthcare services, namely, treatment of patients for infectious diseases or medical disorders; Medical and healthcare information, consultancy and advisory services relating to infections, viruses, SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood borne pathogen, vector borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Providing a web site featuring medical information; Health care services, namely, disease management programs; Telehealth services, namely, providing telemedicine and services in conjunction with providing medical and healthcare services; Mobile healthcare services in the field of Covid-19 and other infectious disease testing, health assessments, and intravenous infusion therapy; Medical screening services in the field of Covid-19 and other infectious diseases in a patient; Polymerase chain reaction (PCR) testing, rapid body antigen testing, and nucleic acid amplification testing for identifying and testing pathogens and biomarkers in respiratory droplets for medical diagnostic purposes related to COVID-19 and other infectious diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LivePerson, Inc.
- Other trademarks owned by LivePerson, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BELLA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 12, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 12, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 20, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 19, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 19, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 12, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 12, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 19, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 19, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 19, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 14, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 12, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 12, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 12, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 16, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 12, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 17, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 17, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 27, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 13, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 12, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 12, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 12, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 8, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 8, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 8, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 13, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 13, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 13, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 5, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 5, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 5, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 7, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 12, 2021 | NWAP | NEW APPLICATION ENTERED | — |